For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Chemokine ligand 4 (CXCL4), otherwise known as platelet factor 4 (PF4) is a small 8 kDa cytokine belonging to the CXC chemokine family. During platelet aggregation, CXCL4/PF4 is released from alpha-granules of activated platelets. The active protein is a tetramer ring of PF4 subunits which binds with high affinity to heparin. The function of CXCL4/PF4 is to promote blood clotting by neutralization of the anticoagulant effect of heparin molecules, by binding them on the endothelial surface of blood vessels. Mature human CXCL4/PF4 shares 96% amino acid sequence identity with the variant CXCL4L1/PF4V and 75% with mouse CXCL4/PF4. During heparin administration, some patients generate antibodies against the CXCL4/PF4/heparin complex, which activate platelets and can cause heparin-induced thrombocytopenia (HIT) and/or arterial thrombosis. The CXCL4/PF4 AlphaLISA detection kit allows for the detection of CXCL4/PF4 in human serum, plasma, and cell culture supernatants.
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
|Assay Target Class||Cytokine|
|Experimental Type||In vitro|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||500 assay points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater ...